Joint Venture2 Mar 2026, 02:48 pm
Emcure Pharmaceuticals and Roche Sign Distribution Agreement to Strengthen Nephrology and Transplant Care in India
AI Summary
Emcure Pharmaceuticals has signed a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. The agreement includes Roche’s established brands like CellCept®, Mircera®, and Neorecormon®. This partnership aims to expand patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India. Emcure, a market leader in anemia management, will distribute these products through its strong network, enabling access to a wider cross-section of patients.
Key Highlights
- Emcure Pharmaceuticals and Roche sign a distribution agreement for select products in the nephrology and transplant medicine portfolio.
- The agreement includes Roche’s established brands like CellCept®, Mircera®, and Neorecormon®.
- The partnership aims to expand patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India.
- Emcure, a market leader in anemia management, will distribute these products through its strong network.
- This partnership enables access to a wider cross-section of patients.